Support for Correlates of Protection efforts associated with the C113 phase 2b trial of MTBVAC in IGRA+, HIV- African adults and adolescents (360G-Wellcome-318910_Z_24_Z)
IAVI will be conducting a phase 2b trial assessing MTBVAC efficacy in preventing TB in 4,300 Interferon Gamma Release Assay (IGRA)+, HIV- African adults and adolescents (the C113 trial). Safety and immunogenicity of MTBVAC will be assessed as secondary objectives. It will be essential to collect and store blood specimens to permit assessments of correlates of immune protection (CoP) should the vaccine prove efficacious. The identification of one or more immune correlates of protection against developing TB disease would represent a major breakthrough, hastening the development of future TB vaccines. This grant will support the collection, shipping, and storage of specimens for CoP analysis during the trial and will fund the biorepository, where the specimens will be stored for 10 years and made available for future CoP analyses.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Region | International |
| Award Date | 2024-10-23T00:00:00+00:00 |
| Internal ID | 318910/Z/24/Z |
| Planned Dates: End Date | 2035-10-31T00:00:00+00:00 |
| Planned Dates: Start Date | 2025-11-01T00:00:00+00:00 |
| Amount Awarded | 2283452.67 |
| Financial Year | 2024/25 |
| Lead Applicant | Dr One Dintwe |
| Grant Programme: Title | Discretionary Award |
| Applicant Surname | Dintwe |
| Approval Committee | Discretionary Award decision meeting |
| Recipient Org: Country | United States |
| Recipient Org: City | New York |
| Has the grant transferred? | No |
| Research conducted at multiple locations? | No |
| Total amount including partnership funding | 2283452.67 |